Charles Schwab’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.03B | Sell |
8,155,281
-26,499
| -0.3% | -$3.49M | 0.14% | 121 |
|
|
2026
Q1 | $1.14B | Buy |
8,181,780
+174,990
| +2% | +$24.5M | 0.17% | 97 |
|
|
2025
Q4 | $983M | Buy |
8,006,790
+75,930
| +1% | +$9.23M | 0.15% | 111 |
|
|
2025
Q3 | $880M | Sell |
7,930,860
-69,214
| -0.9% | -$7.87M | 0.14% | 122 |
|
|
2025
Q2 | $887M | Sell |
8,000,074
-10,427
| -0.1% | -$1.11M | 0.15% | 113 |
|
|
2025
Q1 | $898M | Buy |
8,010,501
+7,722
| +0.1% | +$797K | 0.17% | 104 |
|
|
2024
Q4 | $739M | Buy |
8,002,779
+249,804
| +3% | +$22.5M | 0.14% | 126 |
|
|
2024
Q3 | $650M | Buy |
7,752,975
+224,960
| +3% | +$17.2M | 0.12% | 142 |
|
|
2024
Q2 | $516M | Buy |
7,528,015
+160,755
| +2% | +$10.7M | 0.1% | 175 |
|
|
2024
Q1 | $540M | Buy |
7,367,260
+85,771
| +1% | +$6.6M | 0.12% | 141 |
|
|
2023
Q4 | $590M | Buy |
7,281,489
+87,482
| +1% | +$6.81M | 0.15% | 118 |
|
|
2023
Q3 | $539M | Sell |
7,194,007
-58,198
| -0.8% | -$4.48M | 0.15% | 113 |
|
|
2023
Q2 | $559M | Sell |
7,252,205
-149,444
| -2% | -$11.9M | 0.16% | 111 |
|
|
2023
Q1 | $614M | Sell |
7,401,649
-147,480
| -2% | -$12.2M | 0.19% | 102 |
|
|
2022
Q4 | $648M | Buy |
7,549,129
+126,762
| +2% | +$10M | 0.21% | 94 |
|
|
2022
Q3 | $458M | Buy |
7,422,367
+301,670
| +4% | +$19M | 0.16% | 115 |
|
|
2022
Q2 | $440M | Sell |
7,120,697
-130,735
| -2% | -$8.09M | 0.15% | 117 |
|
|
2022
Q1 | $431M | Buy |
7,251,432
+21,422
| +0.3% | +$1.37M | 0.13% | 139 |
|
|
2021
Q4 | $525M | Buy |
7,230,010
+168,674
| +2% | +$11.6M | 0.16% | 119 |
|
|
2021
Q3 | $493M | Buy |
7,061,336
+113,605
| +2% | +$7.98M | 0.16% | 112 |
|
|
2021
Q2 | $478M | Buy |
6,947,731
+538,153
| +8% | +$35.9M | 0.16% | 117 |
|
|
2021
Q1 | $414M | Sell |
6,409,578
-124,907
| -2% | -$8.05M | 0.15% | 123 |
|
|
2020
Q4 | $381M | Buy |
6,534,485
+18,926
| +0.3% | +$1.14M | 0.15% | 127 |
|
|
2020
Q3 | $412M | Sell |
6,515,559
-390,755
| -6% | -$27.1M | 0.19% | 106 |
|
|
2020
Q2 | $531M | Sell |
6,906,314
-220,645
| -3% | -$16.9M | 0.26% | 76 |
|
|
2020
Q1 | $533M | Buy |
7,126,959
+92,451
| +1% | +$6.39M | 0.31% | 62 |
|
|
2019
Q4 | $457M | Buy |
7,034,508
+110,591
| +2% | +$7.2M | 0.25% | 74 |
|
|
2019
Q3 | $439M | Buy |
6,923,917
+145,309
| +2% | +$9.5M | 0.26% | 71 |
|
|
2019
Q2 | $458M | Buy |
6,778,608
+131,451
| +2% | +$8.65M | 0.28% | 66 |
|
|
2019
Q1 | $432M | Buy |
6,647,157
+591,767
| +10% | +$39.3M | 0.28% | 66 |
|
|
2018
Q4 | $379M | Buy |
6,055,390
+232,046
| +4% | +$16.2M | 0.29% | 62 |
|
|
2018
Q3 | $450M | Buy |
5,823,344
+356,677
| +7% | +$26.9M | 0.3% | 57 |
|
|
2018
Q2 | $387M | Buy |
5,466,667
+241,676
| +5% | +$17.1M | 0.28% | 59 |
|
|
2018
Q1 | $394M | Buy |
5,224,991
+64,494
| +1% | +$5.13M | 0.31% | 54 |
|
|
2017
Q4 | $370M | Buy |
5,160,497
+201,109
| +4% | +$15.3M | 0.29% | 54 |
|
|
2017
Q3 | $402M | Buy |
4,959,388
+252,556
| +5% | +$19.3M | 0.35% | 46 |
|
|
2017
Q2 | $333M | Buy |
4,706,832
+302,787
| +7% | +$20.1M | 0.31% | 49 |
|
|
2017
Q1 | $299M | Buy |
4,404,045
+150,318
| +4% | +$10.6M | 0.3% | 51 |
|
|
2016
Q4 | $305M | Buy |
4,253,727
+198,523
| +5% | +$14.8M | 0.33% | 46 |
|
|
2016
Q3 | $321M | Sell |
4,055,204
-738,815
| -15% | -$60M | 0.38% | 43 |
|
|
2016
Q2 | $400M | Sell |
4,794,019
-202,214
| -4% | -$17.9M | 0.5% | 37 |
|
|
2016
Q1 | $459M | Sell |
4,996,233
-176,981
| -3% | -$16M | 0.6% | 30 |
|
|
2015
Q4 | $523M | Buy |
5,173,214
+79,614
| +2% | +$8.28M | 0.7% | 24 |
|
|
2015
Q3 | $501M | Buy |
5,093,600
+86,728
| +2% | +$9.63M | 0.74% | 20 |
|
|
2015
Q2 | $586M | Buy |
5,006,872
+55,899
| +1% | +$6.11M | 0.81% | 14 |
|
|
2015
Q1 | $486M | Buy |
4,950,973
+127,258
| +3% | +$12.9M | 0.68% | 23 |
|
|
2014
Q4 | $455M | Buy |
4,823,715
+670,256
| +16% | +$69.3M | 0.68% | 22 |
|
|
2014
Q3 | $442M | Buy |
4,153,459
+387,571
| +10% | +$38M | 0.73% | 21 |
|
|
2014
Q2 | $312M | Buy |
3,765,888
+146,213
| +4% | +$11.4M | 0.53% | 28 |
|
|
2014
Q1 | $256M | Buy |
3,619,675
+283,564
| +8% | +$22.2M | 0.46% | 39 |
|
|
2013
Q4 | $251M | Buy |
3,336,111
+93,306
| +3% | +$6.5M | 0.48% | 36 |
|
|
2013
Q3 | $204M | Buy |
3,242,805
+108,485
| +3% | +$6.48M | 0.41% | 43 |
|
|
2013
Q2 | $162M | Buy |
+3,134,320
| New | +$163M | 0.36% | 52 |
|
Other funds holding GILD
Charles Schwab's GILD Position: Q2 2026 in Review
Charles Schwab reduced its Gilead Sciences (GILD) stake by 0.32% in Q2 2026, selling an estimated $3.49M and leaving 8,155,281 shares worth $1.03B. The position accounts for 0.14% of the portfolio, ranked #121.
Charles Schwab first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.14B in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Charles Schwab held 8,155,281 shares of Gilead Sciences worth $1.03B as of Q2 2026.
- Charles Schwab sold 26,499 Gilead Sciences shares in Q2 2026, an estimated $3.49M.
- Gilead Sciences made up 0.14% of Charles Schwab's portfolio in Q2 2026, its #121 holding.
- Charles Schwab first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Gilead Sciences position peaked at $1.14B in Q1 2026.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.